RELATED CONTENT
News
Compañía Mexicana de Radiología, CGR, S.A. de C.V. (CMR) acquired certain Naviscan Inc. assets, including intellectual property and the Naviscan trademark.
December 11, 2013 
Feature
According to a new market research report "Breast Imaging Technologies Market (Digital Mammography,3D Breast Tomosynthesis, Breast MRI, Breast Ultrasound, Molecular Breast Imaging, Optical Imaging, PET/CT/PEM Modalities) Technology and Market Analysis & Global Forecasts to 2017" is an attempt to showcase the market impact of current and emerging breast imaging technologies having excellent growth potential in the coming five years. The technologies profiled in the report are segmented into Ionizing breast imaging modalities and Non-Ionizing breast imaging technologies on basis of radiation. Ionizing breast imaging modalities include Mammography, 3D Breast Tomosynthesis, Cone beam Computed Tomography (CBCT), Positron Emission Mammography (PEM), Molecular Breast Imaging (MBI), Positron Emission Tomography (PET) and Breast Specific Gamma Imaging (BSGI). The various Non-ionizing modalities for breast screening covered in the report are Breast MRI, Optical Imaging, Breast thermography and Breast Ultrasound.
January 11, 2013 
Feature | Roberto Aranibar
Over the last few years, new legislation mandating the inclusion of breast density findings in results letters sent to women after their mammography exams has begun appearing in a growing number of states. With three states having already enacted such laws, 17 states working on similar legislation and a federal bill recently introduced in the U.S. House of Representatives, Frost & Sullivan expects widespread breast density reporting laws to have a significant impact on the demand for and utilization of various breast screening technologies.
October 25, 2012 
Feature | Tricia Peters, CNMT, PET
Positron emission mammography (PEM) is an imaging technique designed to provide metabolic visualization of lesions in the breast tissue. The Naviscan high-resolution PEM system is a dual-detector system consisting of two flat, high-resolution detector heads using lutetium yttrium oxyorthosilicate in a 2 x 2 x 13 mm size. The detectors are mounted inside mammogram compression paddles with a 17 x 24 cm field of view. The paddles can be rotated to optimize imaging to match images acquired in standard mammograms. This allows for direct comparison with mammogram images.
September 05, 2012 News
June 15, 2012 — Several groundbreaking studies on the Naviscan PET scanner, the breast application for which is positron emission mammography (PEM), were presented this week at the annual meeting of the Society of Nuclear Medicine (SNM) in Miami, Fla.
June 15, 2012 
News
March 9, 2012 — Researchers from Boca Raton Regional Hospital in Boca Raton, Fla., showed that the FDG dose for positron emission mammography (PEM) may be reduced by up to 50 percent without impacting sensitivity.
March 09, 2012 
News
January 12, 2012 — UT-Southwestern Medical Center in Dallas, Texas, has acquired and installed a high-resolution positron emission tomography (PET) scanner.
January 12, 2012 
News
October 31, 2011 – The Breast journal published new data from a prospective study conducted at the Seoul National University College of Medicine in Korea that shows positron emission mammography (PEM) has a higher sensitivity for tumor detection compared with whole-body positron emission tomography (PET)/ computed tomography (CT) when using both visual as well as quantitative analysis. These results were particularly striking and significant for smaller-sized tumors (less than 2 cm), likely due to the improved spatial resolution offered by PEM. This demonstrates PEM's clinical utility in being able to more effectively diagnosis early stage cancer.
October 31, 2011 
News
October 21, 2011 — The National Institute of Cancer (INCan) is the first to offer positron emission mammography (PEM) to the residents of Mexico. PEM is the breast application of the Naviscan high-resolution positron emission tomography (PET) scanner that shows the location as well as the metabolic phase of a lesion. It is the only U.S. Food and Drug Administration (FDA)-cleared 3-D molecular breast imaging (MBI) device on the market.
October 21, 2011 
News
September 8, 2011 — Naviscan announced it obtained CE Mark approval for its high-resolution positron emission tomography (PET) scanner and PET-guided biopsy accessory. The breast application of the scanner is positron emission mammography (PEM). Naviscan has expanded its distribution into 13 European countries and has already received its first two orders in Germany and Switzerland.
September 08, 2011 